Approval · Notice of Compliance 9604 · 2008
PRADAX: Notice of Compliance 9604
Issued June 10, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9604
- Date
- June 10, 2008
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Anticoagulant
Products in this notice
Medicinal ingredients
- DABIGATRAN ETEXILATE MESILATE 75 MG per CAP
- DABIGATRAN ETEXILATE 110 MG per CAP